Anavex Life Sciences (NASDAQ:AVXL) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL - Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. HC Wainwright currently has a $40.00 target price on the biotechnology company's stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Anavex Life Sciences to a "strong-buy" rating in a report on Monday, July 22nd.

Anavex Life Sciences Trading Up 2.6 %

Shares of NASDAQ:AVXL traded up $0.15 during mid-day trading on Friday, reaching $5.65. The stock had a trading volume of 439,938 shares, compared to its average volume of 1,154,929. The firm has a 50 day simple moving average of $5.68 and a two-hundred day simple moving average of $4.95. Anavex Life Sciences has a twelve month low of $3.25 and a twelve month high of $10.45. The firm has a market cap of $478.23 million, a PE ratio of -11.30 and a beta of 0.61.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. During the same quarter in the prior year, the firm earned ($0.14) EPS. On average, equities analysts anticipate that Anavex Life Sciences will post -0.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Anavex Life Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in AVXL. Creative Planning increased its holdings in Anavex Life Sciences by 54.2% during the third quarter. Creative Planning now owns 39,871 shares of the biotechnology company's stock worth $226,000 after buying an additional 14,010 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Anavex Life Sciences by 106.2% in the 3rd quarter. SG Americas Securities LLC now owns 27,706 shares of the biotechnology company's stock valued at $157,000 after acquiring an additional 14,272 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Anavex Life Sciences by 8.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company's stock worth $129,000 after purchasing an additional 2,401 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new stake in shares of Anavex Life Sciences in the 2nd quarter valued at about $346,000. Finally, AQR Capital Management LLC lifted its stake in Anavex Life Sciences by 145.8% in the 2nd quarter. AQR Capital Management LLC now owns 45,219 shares of the biotechnology company's stock valued at $191,000 after purchasing an additional 26,821 shares during the last quarter. Institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.